Curis, Inc., a drug discovery and development company, engages in the research and development of cancer therapeutics. It develops Erivedge (vismodegib) capsule, an orally-administered small molecule Hedgehog pathway inhibitor that has received FDA approval for the treatment of adults with advanced forms of basal cell carcinoma; and is in a phase II clinical trial for the treatment of patients with operable nodular basal cell carcinoma. The company also develops CUDC-101, which is under phase I expansion trial for the treatment of specific tumor types, including head and neck, non-small cell lung, breast, gastric, and liver cancers; and CUDC-907, an orally bioavailable, network-targeted small molecule that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase. In addition, it is involved in a research program, which comprises Debio 0932 that is under phase Ib clinical trial to treat patients suffering from advanced solid tumors. The company has collaborations with Genentech, Inc. for developing Erivedge (vismodegib) capsule; and with Debiopharm S.A. for developing Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.